Scientists discover the key to hepatitis A virus replication
With no current treatments for hepatitis A, scientists have discovered how a protein and enzymes interact to allow hepatitis A virus to replicate.
List view / Grid view
In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.
With no current treatments for hepatitis A, scientists have discovered how a protein and enzymes interact to allow hepatitis A virus to replicate.
A new insight into the way the EGF receptor sends signals into cells could help researchers design new cancer drugs that target this protein.
4 July 2022 | By Eurofins Discovery
In this on-demand webinar, an assay strategy to assess transport-mediated drug interactions that complies with regulations is examined.
A £4.25 million research grant has been awarded seeks to discover meaningful MND treatments within years.
Senior scientist Dr Tony Oosterveen discusses bit.bio’s new ioDisease Model portfolio, including new models for Huntington’s disease to help advance in vitro research and drug discovery.
A new photonic effect in semiconducting helical particles with nanoscale dimensions has been discovered by an international team of scientists from the University of Bath, UK and the University of Michigan, US. Here, Professors Nicholas Kotov and Ventsislav Valev discuss their study and the observed effect which has the potential…
In this issue are articles focusing on a novel stem cell therapy for hearing loss, how a non-linear chiroptical effect could aid drug discovery and the advantages of cryo-electron tomography for imaging research. Also included are pieces on gene therapy, spheroids and genomics.
9 June 2022 | By Eurofins DiscoverX
Watch this on-demand virtual roundtable to explore how the simple, thaw-and-use bioassay format improves assay workflow and helps attain high assay reproducibility.
27 May 2022 | By bit.bio
This webinar explores how a new generation of reproducible and scalable human cell models are being utilised for drug discovery in Huntington’s disease.
Researchers have developed a novel class of therapeutics, called feedback disruptors, that could have the potential to be resistance-proof drugs.
Scientists have developed a deep learning-based model trained on drug-induced gene expression signatures to predict drug-drug interactions.
Scientists have gained new insights into the way G protein-coupled receptors operate, a step toward the development of improved drugs with fewer side effects.
The novel screening technique can identify molecules that can disable dangerous proteins before they cause diseases by blocking them from interacting with a cell’s DNA.
Scientists at the Endocrine Society have found extracellular vesicles may offer new insights into treating endocrine disorders.
By screening various drugs, a new study has found a childhood leukaemia therapeutic is also efficient in treating bladder cancer.